Pipeline

Nuvation Bio is focused on treating patients with the most difficult-to-treat cancers, for which conventional therapies have failed. We are advancing up to six compounds that have resulted from our drug discovery and development programs, which include a cyclin-dependent kinase (CDK) inhibitor program, a BET inhibitor program, a WEE1 inhibitor program, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform that to date has yielded investigational compounds targeting hormone-driven cancers such as prostate, breast and ovarian cancers.

The U.S. Food and Drug Administration (FDA) accepted our first Investigational New Drug (IND) application,and we initiated a Phase 1/2 study of our lead investigational compound, NUV-422, a CDK2/4/6 inhibitor, in patients with high-grade gliomas, including glioblastoma multiforme (GBM), in December 2020. We anticipate submitting up to five additional INDs by 2026 for therapies targeting some of the most difficult-to-treat solid tumors and hematologic cancers.

PROGRAM

PRODUCT CANDIDATE

POTENTIAL INDICATION(S)

PRECLINICAL

PHASE 1

CDK 2/4/6
NUV-422
High-grade Glioma
Metastatic Brain Tumors
ER + MBC
mCRPC
BET
NUV-868
Acute Myeloid Leukemia
WEE1
NUV-569
Pancreatic Cancer
A2A
NUV-1182
IO Combination Study
Drug-Drug
DDC1 (PARP – AR)
Prostate Cancer
Conjugate (DDC)
DDC2 (PARP – ER)
Breast Cancer
Platform
Ovarian Cancer
DDC3
Undisclosed
DDC4
Undisclosed

PROGRAM

PRODUCT CANDIDATE

POTENTIAL INDICATION(S)

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

CDK 2/4/6
NUV-422
High-grade Glioma
Brain metastases
ER + MBC
mCRPC
BET
NUV-868
Acute Myeloid Leukemia/solid tumors
WEE1
NUV-569
Pancreatic Cancer/other solid tumors
A2A
NUV-1182
IO Combination Study
Drug-Drug
DDC1 (PARP – AR)
Prostate Cancer

Conjugate (DDC) Platform

DDC2 (PARP – ER)
Breast Cancer and Ovarian Cancer